SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Cardiovascular Pharmacology and Therapeutics
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Sharma, S.
Right arrow Articles by Lardizabal, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sharma, S.
Right arrow Articles by Lardizabal, J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Intracoronary Administration of Abciximab During Percutaneous Coronary Interventions: Should This Be the Routine and Preferred Approach?

Sanjiv Sharma, MD, FACC, FSCAI

Division of Cardiology, Bakersfield Heart Hospital, Bakersfield, Calif, sanjiv1122{at}yahoo.com

Raj Makkar, MD, FACC, FSCAI

Cardiovascular Intervention Center, Cedars Sinai Medical Center, Los Angeles, California

Joel Lardizabal, MD

Department of Medicine, Kern Medical Center, Bakersfield, California

The authors have had experience with administering abciximab as an intracoronary bolus in 96 high-risk patients undergoing percutaneous coronary interventions, specifically in situations in which there was anticipation of a high embolic load from thrombus/plaque burden at the site of the culprit lesion, saphenous vein graft culprit lesion, threatened abrupt closure, developing slow-flow, or no-reflow phenomena with distal embolization. Our uncontrolled data basically substantiate the safety of intracoronary administration of abciximab. The data summarizing the potential superiority of this method of administration of the drug and the likely mechanisms of this effect are summarized. These incite a need for reevaluation of the method of administration of the drug, especially in high-risk percutaneous coronary interventions cases

Key Words: abciximab • intracoronary • percutaneous coronary intervention

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 11, No. 2, 136-141 (2006)
DOI: 10.1177/1074248406288761
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 J CARDIOVASC PHARMACOL THERHome page
S. S. Patel, H. Rana, and D. A. N. Mascarenhas
Intracoronary Abciximab Use in Patients Undergoing PCI at a Community Hospital: A Single Operator Experience
Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2008; 13(2): 89 - 93.
[Abstract] [PDF]


Advertisement